Century Civil Transforms! Chaohwa Biomed Expands to Malaysia, Plans IPO by 2027

As global populations age, demand for precision medicine and preventive healthcare is experiencing explosive growth. AI-driven large-scale health management has become a core battleground for multinational capital and tech giants. Riding this wave, Century Civil* (5314) has actively transformed into the big health industry in recent years, demonstrating strong operational momentum. Its flagship brand, 'Chaohwa Biomed,' is now initiating international expansion, with Malaysia as its first overseas market.

Chairman Chang Yu-Ming of Century Civil* stated that the group's 'puzzle-piece acquisition' strategy centers on 'operational closure and commercial monetization.' By integrating upstream innovative ingredient development, CDMO (contract development and manufacturing), brand management, and omnichannel sales, the company has successfully built a one-stop big health ecosystem. The biotech health business is expected to achieve record-high performance this year, driven by the growth of its core brands and overseas market expansion.

Chang pointed out that while Taiwan possesses world-class biotech R&D capabilities, it generally lacks the ability to commercialize innovations and expand into international markets. Century Civil* leverages capital strategy to unite two core engines: 'Shiheng Biotech,' focusing on innovative ingredient distribution and academia-industry research integration, and 'Chaohwa Biomed,' dedicated to end-consumer brand operations. Through diverse sales channels such as TV shopping, e-commerce platforms, and live commerce group buying, the company has created a high-growth business model, achieving vertical integration of 'front store, back factory' and avoiding the profit dilution caused by multiple intermediary layers.

According to Chairman Chang, Taiwan's health food market has surpassed NT$180 billion, with consumers increasingly demanding 'data-backed evidence' and 'high absorption efficiency.' However, most exosome (Exosomes) products in the market remain limited to topical application or injection. In contrast, Chaohwa Biomed, a core brand under Century Civil*, has broken away from traditional single-ingredient price wars by leveraging its patented plant-derived technology 'EOB686®' to gain significant market attention.

Chaohwa Biomed vividly describes its complex biotech mechanism as a 'precision missile for the body,' emphasizing that its products can cross digestive barriers and deliver key nutrients and repair factors precisely to targeted areas. EOB686® stabilizes nano-sized exosomes through encapsulation, successfully developing Taiwan's first safe oral exosome product line. Flagship products include 'Weigu Mi' for joint function support and 'Xueji Mi' for ultimate skin beauty. These products not only overcome the low bioavailability bottleneck of traditional supplements but also rapidly gain traction on social media and digital platforms due to their positioning of 'precision and noticeable effects.' Cumulative sales in Taiwan have exceeded one million units, with a repurchase rate surpassing 80%, demonstrating exceptional brand loyalty and profitability. This injects high-margin consumer goods cash flow into Century Civil, serving as the core pillar driving the group's revenue surge.

Looking ahead, Century Civil* maintains a cautiously optimistic outlook. Beyond deepening its presence in Taiwan, Chaohwa Biomed will leverage digital customer acquisition and cross-border e-commerce ecosystems to fully launch its international expansion, initially targeting Malaysia—the strategic core market in Southeast Asia. With localized marketing and sales systems, the company aims to bring high-quality Taiwanese biotech products to the global stage.

Chairman Chang revealed that as overseas operations continue to expand and revenue scales grow, Chaohwa Biomed has established a clear capital market roadmap, aiming to maximize value and deliver long-term returns for Century Civil Group shareholders.